Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04087681 · ClinicalTrials.gov registry record
Study to Collect Information About Invasive Disease Caused by Extraintestinal Pathogenic Escherichia Coli (EXPECT-1)
A clinical trial of E Coli Infections, sponsored by MJM Bonten.
- Completed
- Registry status
- 4,479
- Enrollment target
- 8
- Study locations
NCT04087681: Completed study of E Coli Infections, sponsored by MJM Bonten.
NCT04087681 is a study of E Coli Infections that has completed, run by MJM Bonten. The registered enrollment target is 4,479 participants, above the 78-participant average among 4 other E Coli Infections trials with a reported enrollment target (5642% higher). The trial reports 8 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04087681, a study of E Coli Infections, has completed, sponsored by MJM Bonten.
- COMPLETED
- Registry status
- 4,479 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to collect information from study participants who develop an invasive disease caused by Extraintestinal pathogenic E. coli (ExPEC) during a period of 12 months. This information will be used to support the development of a new vaccine to prevent ExPEC infections.
Primary Outcome
Participant enrolment rate (% of patients screened/invited vs. enrolled)
Conditions Studied
Study Locations (8)
Other
- Duke Clinical Research Institute - Greater Sudbury
- Chu Limoges - Cic - Limoges
- UKK Uniclinic Cologne - Cologne
- University of Verona - Verona
- - Andalusian Public Foundation for Health Research Management in Seville (FISEVI) - Seville
- University of Oxford - Oxford
North Carolina
- Duke Clinical Research Institute - Durham
Chiyoda-ku
- Janssen Pharmaceutical K.K. - Tokyo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,479 participants |
| Start Date | 2019-09-28 |
| Est. Completion | 2021-06-21 |
What the finished NCT04087681 record still lists
NCT04087681 is an observational study that tracks outcomes without assigning an intervention. Its 4,479 participants enrollment target places it among the larger protocols in the corpus, above the 78-participant average among 4 other E Coli Infections trials with a reported enrollment target (5642% higher).
The record links to 1 condition, with E Coli Infections appearing as the primary indexed condition, and to 0 interventions.
NCT04087681 lists 8 locations in 3 states (Other, North Carolina, Chiyoda-ku).
Frequently Asked Questions
What is clinical trial NCT04087681 about?
NCT04087681 is a clinical study titled "Study to Collect Information About Invasive Disease Caused by Extraintestinal Pathogenic Escherichia Coli (EXPECT-1)". The purpose of this study is to collect information from study participants who develop an invasive disease caused by Extraintestinal pathogenic E. coli (ExPEC) during a period of 12 months. This information will be used to support the development of a new vaccine to prevent ExPEC infections.
What is the current status of trial NCT04087681?
This trial is currently completed. The enrollment target is 4,479 participants. The study started on 2019-09-28. Estimated completion is 2021-06-21.
What conditions does trial NCT04087681 study?
This clinical trial studies the following conditions: E Coli Infections.
Who is sponsoring clinical trial NCT04087681?
This trial is sponsored by MJM Bonten, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04087681 being conducted?
This trial has 8 study locations across North Carolina, Chiyoda-ku. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for E Coli Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant
RECRUITING · Phase 1
-
Clinical and Microbiologic Characteristics of Cephalosporin-Resistant E. Coli-PITT Protocol
COMPLETED
-
Community - Associated Extended-spectrum Beta-lactamases (ESBL)
COMPLETED
-
A Study Investigating the Safety, Recovery, and Pharmacodynamics of Multiple Oral Administrations of SNIPR001 in Healthy Subjects
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06252753 · 4,490 participants
Observational Study Protocol: LIVER-R
- NCT06533111 · 4,500 participants · NA
Improving Surgical Patient Outcomes Through Implementation of a SemiStructured Intraoperative Anesthesia Handoff Tool
- NCT06588452 · 4,500 participants
Manual Versus AI-Assisted Clinical Trial Screening Using Large-Language Models
- NCT07165028 · 4,500 participants · Phase 3
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI